<DOC>
	<DOC>NCT01397240</DOC>
	<brief_summary>The purpose of this study is to research the safety and efficacy of Albis® for the prevention of aspirin-induced gastrointestinal ulcers in patients taking low-dose aspirin.</brief_summary>
	<brief_title>The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients</brief_title>
	<detailed_description>The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients taking Low-dose Aspirin, A pilot study Double-Blind, Placebo-Controlled, Randomized, Multicenter, Parallel, Prospective study</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Male or female, aged 20 to 80 years Subjects identified with at least one of the following diagnosis (Angina, Myocardial Infarction(Old), Cerebrovascular Disease, Peripheral Vascular Disease, Diabetes, Hypertension, Hypercholeseterolemia, Obesity) who are required to take a low dose of Aspirin (100mg/day) for more than 12 weeks. Females who are pregnant, nursing, or planning a pregnancy during the study period or females of childbearing potential Peptic ulcer or Reflux oesophagitis hemostatic disorder or coagulation disorder Known allergy or hypersensitivity to the study medication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>